Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0G1YO
|
||||
| Former ID |
DCL000411
|
||||
| Drug Name |
GSK1521498
|
||||
| Synonyms |
GSK-1521498; GSK-1521498B
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Obesity [ICD9: 278; ICD10:E66] | Phase 1 | [1] | ||
| Company |
GlaxoSmithKline
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C24H20F2N4
|
||||
| Canonical SMILES |
C1C(CC2=CC=CC=C21)NCC3=C(C=C(C=C3F)C4=CC(=CC=C4)C5=NC=N<br />N5)F
|
||||
| InChI |
1S/C24H20F2N4/c25-22-11-19(15-6-3-7-18(8-15)24-28-14-29-30-24)12-23(26)21(22)13-27-20-9-16-4-1-2-5-17(16)10-20/h1-8,11-12,14,20,27H,9-10,13H2,(H,28,29,30)
|
||||
| InChIKey |
WIEDUMBCZQRGSY-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Mu-type opioid receptor | Target Info | Agonist | [1], [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Estrogen signaling pathway | |||||
| Morphine addiction | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Enkephalin release | |||||
| Pathway Interaction Database | IL4-mediated signaling events | ||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | TCR Signaling Pathway | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Peptide GPCRs | |||||
| Opioid Signalling | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Clinical pipeline report, company report or official report of GlaxoSmithKline (2011). | ||||
| REF 2 | Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.